MOSCOW, January 1. /TASS/. The Federal Register of HIV patients, set to be launched in Russia’s regions on January 1, will help provide patients with medicine, Health Ministry Spokesman Oleg Salagai told TASS. “Any individual diagnosed with HIV should be interested in being included in this ...

The success of recent local and state initiatives to end HIV as an epidemic will hinge on community mobilization efforts to inspire engagement in care and services, along with meaningful involvement at all levels of advocacy and policy, according to Community Mobilization: An Assessment of ...

Investigators claim VMMC scale-up plus 90-90-90 could end HIV, not just AIDS Scale-up of voluntary medical male circumcision (VMMC) in countries with a high HIV prevalence has the potential to reduce incidence of new infections over and above the level associated with attainment of the 90-90-90 ...

Static picture in other countries conceals local change, especially in gay men The annual number of new cases of HIV increased by at least 8% in 2015 in the whole of the World Health Organization’s European region, and by 60% in the last decade, according to ...

IAPAC launched Recommendations for the Rapid Expansion of HIV Self-Testing in Fast-Track Cities during a joint Brazilian National STI, HIV/AIDS & Viral Hepatitis Program – IAPAC meeting of that country’s cities held January 26, 2017, in Brasília. Developed in collaboration with ASLM, the recommendations promote ...

European doctors ask the question at 2016 Standard of Care meeting The purpose and structure of clinical HIV guidelines may have to change radically now that universal treatment on diagnosis is the clinical consensus, physicians from the European AIDS Clinical Society (EACS) heard in a meeting ...

UCLA-led researchers suggest that blocking type I interferon may help combat the virus that causes AIDS In findings they call counterintuitive, a team of UCLA-led researchers suggests that blocking a protein, which is crucial to initiating the immune response against viral infections, may actually help combat ...

A Q&A with HIV cure science superstars What’s going on in HIV cure research? Is it ethical to take people off of HIV antiretrovirals if they participate in HIV cure research? And, do you think we’ll have a functional cure for HIV in the next few ...

From February 2016 to December 2016, five EU countries reported clusters or sporadic cases associated with two different hepatitis A virus sequences. Three other countries, Spain, Italy and Germany, reported regional increases of hepatitis A in men who have sex with men (MSM) or adult ...

Geneva, 21 December 2016 – In an effort to accelerate progress towards ending TB, WHO’s Global TB Programme (GTB) has established the first Global TB Research Task Force. The Task Force, comprising of 19 TB programme, research financing, technical, civil society and academic experts, chaired by ...

STAND trial will not re-open patient enrollment NEW YORK (21 December, 2016)—TB Alliance announced, based on positive results from the Phase 2b NC-005 trial, that it will now plan a Phase 3 study to test the BPaMZ (bedaquiline + pretomanid + moxifloxacin + pyrazinamide) regimen. In ...

When initiated and taken every day exactly as prescribed and directed, HIV treatment(ART) can greatly reduce the amount of HIV in the blood (viral load), allowing the immune system to begin the process of gradually repairing itself. As the use of ART continues, the amount ...

In an article published in PLOS ONE, Professor Jean-Paul Viard, MD, from the Assistance Publique–Hôpitaux de Paris, and colleagues, explore a potential link between higher basal vitamin D levels in HIV-positive patients and a stronger immune response to hepatitis B and Streptococcus pneumoniae vaccination. Vitamin D ...

Investigators from Whitehead Institute, the Ragon Institute of MGH, MIT and Harvard and the Broad Institute of MIT and Harvard have used CRISPR-Cas9 gene-editing technology to identify three promising new targets for treatment of HIV infection. In their report receiving advance online publication in Nature ...

The Lancet HIV is an exclusively online journal dedicated to publishing original research that advocates change in, or illuminates, HIV clinical practice. It publishes translational, epidemiological, clinical, operational, and implementation studies. The January 2017 issue is available here. Original Article

During the early (also known as acute) stage of HIV infection—about two weeks after initial exposure—the amount of virus produced in the body is very high. This occurs because the virus has overwhelmed and subverted the body’s defences. As acute infection is not associated with ...

First phase III studies to show efficacy of two-drug regimen as maintenance therapy London, UK 19 December 2016 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that both of its Phase III ...

Study to test efficacy, safety of injectable cabotegravir compared to daily oral PrEP December 20, 2016 – The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting ...